Ultime notizie per Tempus AI (NASDAQ:TEM) Azioni

TEMPUS AI INC

Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Russia,Moscow,24.06.2021,Logo,Of,Financial,Investing,Fund,Ark,Invest

Equities

News

Short Sellers

Markets

ETFs

ARKG

ARKK

TSLA

Quali sono le ragioni dietro questa decisione e cosa significa per il futuro del colosso dei veicoli elettrici?

Tesla sotto pressione: Ark Invest vende le sue azioni, ma perché?

Kyiv,,Ukraine,-,February,25,,2021:,In,This,Photo,Illustration

ARKF

ARKQ

ARKW

ARKX

NVDA

PLTR

Cathie Wood e Ark Invest rafforzano la loro scommessa sull&#39;intelligenza artificiale con significativi acquisti di azioni Nvidia e AMD.

Ark Invest scommette ancora sull&#39;IA: ecco cosa ha comprato Cathie Wood

Charging,Bull,Is,A,Bronze,Sculpture,That,Stands,On,Broadway,

Market Summary

Broad U.S. Equity ETFs

Futures

General

AAPL

AMZN

GOOGL

I rendimenti degli investimenti di Nancy Pelosi hanno superato quelli di Warren Buffett e Berkshire Hathaway negli ultimi 11 anni.

Nancy Pelosi meglio di Warren Buffett? Ecco come ha battuto l&#39;Oracolo di Omaha

Tempus AI Inc

TEMCO

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Climate Change Solutions ETF

PERSOL HLDG CO LTD ORD by Persol Holdings Co Ltd

Persol Holdings Co Ltd

Tradr 2X Long QBTS Daily ETF Tradr 2X Long TEM Daily ETF

Touchstone ETF Trust Touchstone Sands Capital Emerging Markets ex-China Growth ETF

HC Wainwright &amp; Co. analyst Mitchell Kapoor assumes Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) with a Buy rating and announces Price Target of $15.

Price Target

Initiation

Analyst Ratings

AVTX

HC Wainwright & Co. Assumes Avalo Therapeutics at Buy, Announces Price Target of $15

iShares MSCI Israel Capped Investable Market Index Fund

Reuters Reported Iran Poised To Dismiss US Nuclear Proposal, Citing Iranian Diplomat

CareTrust REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>) ("CareTrust" or the "Company") announced today that, together with a joint venture partner, it has acquired a portfolio of skilled nursing facilities located in the Pacific Northwest for a total purchase price of approximately $146 million, inclusive of transaction costs.
The portfolio consists of 10 facilities comprising 911 licensed beds located across Idaho, Oregon and Washington. The acquisition was completed through a joint venture arrangement entered into between CareTrust and a large third-party healthcare real estate owner. At closing, CareTrust provided common equity and preferred equity investments totaling approximately $141 million at an initial contractual yield on its combined investment in the joint venture of approximately 9.0%. The total investment amount was funded using a combination of cash on hand and a draw from the Company's revolving credit line, which brought the outstanding balance on the revolver to approximately $475 million. The joint venture has leased the facilities to two existing tenants who each have strong rent coverage on existing leased CareTrust properties and deep operating experience pursuant to new 15-year triple-net leases that include extension options and annual escalators.
Joe Callan, Senior Vice President of Investments, added, "This acquisition further underscores the favorable investment environment we are seeing and highlights CareTrust's unique ability to leverage its operator roots to grow our portfolio with high-quality tenants."
The closing of this transaction brings the Company's annual investment total to approximately $1.1 billion. Mr. Callister noted, "After a busy 2024 deploying over $1.5 billion in skilled nursing and seniors housing investments, the momentum continues in 2025. We're excited to announce this transaction after closing the Care REIT acquisition in May to highlight the concurrent opportunities in the US and UK to grow our portfolio. With our balance sheet strength, we're positioned to pursue those opportunities in both markets simultaneously."
 &nbsp;

CTRE

Caretrust REIT Acquires Portfolio Of Skilled Nursing Facilities In Pacific Northwest For About $146M, Inclusive Of Transaction Costs

HC Wainwright &amp; Co. analyst Sean Lee assumes Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) with a Buy rating and announces Price Target of $1.1.

SENS

HC Wainwright & Co. Assumes Senseonics Holdings at Buy, Announces Price Target of $1.1

Broadstone Net Lease Disclosed That Quarter-to-date, It Has Invested $83.3M, Including $54.7M In New Property Acquisitions And $28.6M In Build-to-suit Developments

Effective June 2, 2025, KORE Group Holdings, Inc. (the "Company") appointed Anthony Bellomo as Executive Vice President, Chief Financial Officer &amp; Treasurer of the Company. In connection with such appointment, on May 28, 2025, the Company informed Paul Holtz, the Company's former Executive Vice President, Chief Financial Officer &amp; Treasurer, that he would depart from such role and as an executive officer of the Company effective May 30, 2025. Mr. Holtz is expected to remain employed by the Company in an advisory capacity through June 30, 2025 to effect an orderly transition of duties. In connection with his transition services, Mr. Holtz will continue to be paid his current annual base salary through the time he remains employed, and his outstanding equity awards will continue to vest in accordance with their terms, in each case, subject to his continued employment with the Company. After the end of such transition period, Mr. Holtz will be entitled to severance payments and benefits arising from a termination Without Cause as defined in and as set forth his Employment Agreement, dated April 1, 2022, with the Company, as more fully described in the Current Report on Form 8-K filed by the Company on April 6, 2022.
 &nbsp;
Mr. Bellomo joins the Company from Mitel Networks Corporation, where he spent the last fifteen years in financial roles of increasing responsibility, including having served as Group Vice-President, Finance M&amp;A and Chief Accounting Officer since 2018. Previously, he served in a senior financial role at Onex Corporation and as Audit Manager at Deloitte &amp; Touche LLP. He is a Chartered Accountant in Ontario, Canada, Certified Public Accountant in the State of Illinois and CFA charterholder. Mr. Bellomo has a Bachelor of Mathematics and Master of Accounting from the University of Waterloo in Waterloo, Ontario, Canada.

Management

KORE

KORE Group Names Mitel Exec Anthony Bellomo as New CFO, Replacing Paul Holtz

CareTrust REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>) ("CareTrust") announced today the closing of a new senior unsecured term loan and the hiring of two talented real estate professionals. These actions further bolster its growth platform and strengthen the Company's long-term prospects at a time of accelerating investment in its healthcare portfolio.
New Term Loan
The Company closed on an amendment to its existing credit agreement with KeyBank National Association and a syndicate of leading financial institutions to add a new $500 million unsecured term loan (the "Term Loan") to its existing $1.2 billion unsecured revolving credit facility. The Company currently expects to use borrowings under the Term Loan to pay off the revolver balance of approximately $475 million, to fund acquisitions and for general corporate purposes. The Term Loan initially matures in May 2030, with an uncommitted accordion feature allowing for up to $800 million in additional borrowing capacity.

CareTrust REIT Closes Amendment, Enhancing Credit Facility With $500M Term Loan

B of A Securities analyst Justin Post maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $230 to $248.

B of A Securities Maintains Buy on Amazon.com, Raises Price Target to $248

Piedmont Office Realty Trust Announced That It Has Completed Over 500,000 Square Feet Of Leasing Thus Far In The Second Quarter, With 350,000 Square Feet Related To New Tenants

VIAV

Inertial Labs, A VIAVI Solutions Announced The Launch Of A Visual-aided Inertial Navigation System (VINS) That Enables Aircraft To Maintain Accurate Flightpaths When No Reliable GPS/GNSS Signal Is Available

Liquidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA&#x2122; (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

LQDA

Liquidia Begins Shipping Newly Approved Yutrepia for Rare Lung Diseases Just Days After FDA OK

B of A Securities analyst Ronald Epstein upgrades Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from Neutral to Buy and raises the price target from $185 to $260.

Upgrades

B of A Securities Upgrades Boeing to Buy, Raises Price Target to $260

<ul>
<li>Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p&lt;0.0001)</li>
<li>Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continues</li>
<li>The safety profile of atacicept was favorable, and comparable to placebo</li>
<li>Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in 4Q 2025; ORIGIN 3 trial continues with two-year results expected in 2027</li>
<li>Vera will host a conference call and webcast at 8:00 am ET on Monday, June 2 &nbsp;</li>
</ul>
BRISBANE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults.
Participants treated with atacicept achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p&lt;0.0001) at week 36. For other prespecified endpoints, atacicept treatment also demonstrated results that were consistent with or better than those previously observed in the ORIGIN Phase 2b trial.1 The safety profile of atacicept in this analysis was favorable, and comparable to placebo. Vera plans to share these results with the FDA in the coming weeks, and full results will be submitted to the American Society of Nephrology Kidney Week.

VERA

Vera Therapeutics Says Atacicept ORIGIN Phase 3 Trial Meets Primary Endpoint Of Reduction In UPCR For IgAN Treatment; Vera Currently Plans To Submit BLA For Accelerated Approval To FDA In 4Q 2025

Southwest Airlines And China Airlines Group, A Taiwan-based Carrier, Are In Discussions To Create An Interline Partnership In Early 2026, With Published Connections Expected To Go On Sale Later This Year

Asset Sales

GPUS

Hyperscale Data Announced The Sale Of Its Minority Equity Interest In A Privately Held Pharmaceutical Company For Gross Proceeds Of $4.65M In Cash

HC Wainwright &amp; Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy rating and announces Price Target of $9.

CRDL

HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9

HC Wainwright &amp; Co. analyst Brandon Folkes assumes PolyPid (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) with a Buy rating and announces Price Target of $11.

PYPD

HC Wainwright & Co. Assumes PolyPid at Buy, Announces Price Target of $11

Goldman Sachs analyst Jordan Alliger upgrades Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) from Neutral to Buy and raises the price target from $45 to $65.

Goldman Sachs Upgrades Knight-Swift to Buy, Raises Price Target to $65

Goldman Sachs analyst Jordan Alliger upgrades Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) from Neutral to Buy and raises the price target from $24 to $32.

SNDR

Goldman Sachs Upgrades Schneider National to Buy, Raises Price Target to $32

Legal

Press Releases

Tempus AI, Inc. Investors: Company Investigated by the Portnoy Law Firm

TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting

Small Cap

Opinion

Real-World Deployments Signal AI Healthcare Is Ready for Scale

Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Tempus AI Inc. (NASDAQ: TEM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

Introducing Tempus One in the EHR with Integrated Guidelines

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM

AVAI

BTAI

HWAIF

TSX:AIDX

TSX:WELL

WHTCF

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Tempus AI

Notizie

Ultime notizie per Tempus AI (NASDAQ:TEM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO